{"organizations": [], "uuid": "c2720280094fed1365e55cced2618d5642732e6b", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180115.html", "section_title": "Archive News &amp; Video for Monday, 15 Jan 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-moberg-pharma-receives-favorable-o/brief-moberg-pharma-receives-favorable-outcome-from-nad-idUSFWN1PA037", "country": "US", "domain_rank": 408, "title": "BRIEF-Moberg Pharma Receives Favorable Outcome From NAD", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 1.0, "site_type": "news", "published": "2018-01-15T15:44:00.000+02:00", "replies_count": 0, "uuid": "c2720280094fed1365e55cced2618d5642732e6b"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-moberg-pharma-receives-favorable-o/brief-moberg-pharma-receives-favorable-outcome-from-nad-idUSFWN1PA037", "ord_in_thread": 0, "title": "BRIEF-Moberg Pharma Receives Favorable Outcome From NAD", "locations": [], "entities": {"persons": [{"name": "moberg", "sentiment": "negative"}, {"name": "moberg pharma ab", "sentiment": "negative"}], "locations": [{"name": "u.s.", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "brief-moberg pharma", "sentiment": "negative"}, {"name": "kerasal", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "gdynia newsroom", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Jan 15 (Reuters) - Moberg Pharma Ab (Publ):\n* MOBERG PHARMA RECEIVES FAVORABLE OUTCOME FROM NAD - MAIN COMPETITOR TO DISCONTINUE CURRENT MARKETING\n* EXPECTS OUTCOME TO FURTHER STRENGTHEN KERASAL NAILSÂ® POSITION AND GROWTH PROSPECTS IN U.S. MARKET Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-01-15T15:44:00.000+02:00", "crawled": "2018-01-16T13:25:15.000+02:00", "highlightTitle": ""}